Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Experiences From the First Year of Using Garadacimab to Treat Hereditary Angioedema and Acquired Angioedema

ABSTRACT Background Garadacimab, a first‐in‐class, recombinant monoclonal antibody targeting activated FXII, is available in Germany for long‐term prophylaxis (LTP) of hereditary angioedema (HAE) since March 2025. We aimed to examine garadacimab real‐life treatment outcomes at our Berlin Angioedema Center of Reference...

M. Magerl, K. Schön, J. Ruhe et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.